Integrity Life Sciences gains 510(k) for spinal decompression device; New diagnostic technique uses immune cell DNA;

@FierceMedDev: Devicemaker Avinger pulled in $33M in fundraising to develop catheters. Item | Follow @FierceMedDev

@MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

@DamianFierce: Abbott nabbed a CE mark for a new diabetes diagnostic the company says bests glucose monitors. Article | Follow @DamianFierce

> Pacific Biolabs is predicting that contract research organizations will see a boost in business from devicemakers, as the FDA requires more clinical trials before approval. News

> Researchers at Johns Hopkins say the latest generation of blood sugar-monitoring devices don't just require fewer needle pricks, they're also more effective than traditional methods. Article

> Integrity Life Sciences picked up 510(k) clearance for its Spinal Care System, a non-surgical spinal decompression device. More

> Pentax Medical has launched a new endoscopic ultrasound device in Europe, boasting that its slim insertion tube maximizes patient comfort. Release

> Israel's OrSense is unveiling its new wireless hemoglobin monitor, which, in trials, has demonstrated that it's as effective as invasive techs at identifying anemia and screening blood donors. Report

> A new diagnostic technique developed by scientists from Brown University and elsewhere uses immune cell DNA. Release

Biotech News

 @FierceBiotech: Analysis: Top 20 ‪biotech‬ licensing deals in H1 2012 - a buyer's market dominates the deal scene. Special Report | Follow @FierceBiotech

 @JohnCFierce: J&J licensing a portfolio of diabetes products from Evotec. $8M up, up to $300M down per product in milestones. Release | Follow @JohnCFierce

 @RyanMFierce: Ipsen (France) and Inspiration Biopharma (Cambridge, MA) halt late-stage hemophilia drug trials, program in question. Story | Follow @RyanMFierce

> Ipsen shares slide after FDA orders hold on PhIII hemophilia drug trials. Article

> Struggling Chelsea jettisons staffers, plots survival strategy. Story

> Regulatory setback raises fresh questions about Sanofi R&D comeback. News

Pharma News

 @FiercePharma: Can a new CEO turn Savient around? Regrouping after weak Krystexxa sales, Savient to lay off 35% of workforce. News | Follow @FiercePharma

> Amid Krystexxa woes, Savient plots layoffs and taps new CEO. More

> Forest CEO goes mano-a-mano with Carl Icahn. Item

> Novartis plant snafu sends desperate Excedrin users to eBay. Article

> Ranbaxy lines up plans for U.S. growth. Story

Pharma Manufacturing News

 @EricPFierce: FDA‬ warning letters , 483 reports can suggest a tipping point has been reached by a drug company. How about yours? Special Report | Follow @EricPFierce

> Ireland campus becomes Eli Lilly's launch pad. Story

> Abemarle again expands Michigan API plant. News

> AEI suggests booting WHO drugmakers that don't meet the grade. More

Biotech Research News

> Key molecule spotted as possible lung cancer weapon. Story

> Mouse model connects specific gene to liver cancer advance. Item

> Acadia's Parkinson's drug shows promise in treating Alzheimer's psychosis. More

> Nanomedicine busts deadly clots in promising mouse study. Article

And Finally... The Huffington Post highlights a number of new medical device implants under development or on the market that are designed to help address age-related ailments. Story

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.